Babies born to HIV-positive mothers in Kenya face an increased risk of contracting the virus due to a shortage of critical ...

The study by Sari Reisner and colleagues1 in The Lancet HIV on gender-affirming hormone therapy and its effect on HIV ...

Of those surveyed, 34% believe they are unlikely ever to contract HIV, and 20% said they ‘can’t be bothered’ to test for the ...

If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in ...

Gender-affirming hormone therapy (GAHT) is associated with significantly improved HIV outcomes for transgender, nonbinary, ...

Researchers studied the relationship between age and the risk for skin cancer and oncovirus infections among patients with HIV.

Further studies and clinical trials will be required to evaluate its safety and effectiveness in patients ... medication used to treat and prevent HIV/AIDS. Efavirenz is in a class of medications ...

They found that the majority of HIV-infected ICH patients were middle-aged (35 to 50 years of age) or elderly (60 years of age and older) men in the AIDS stage. Multivariate binary logistic regression ...

The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China. BMC Immunol.

Another initiative, led by indigenous knowledge holder David Molefi, focuses on a supplement designed for HIV/Aids patients. Professor David Katerere, of Tshwane University of Technology ...

It was sent to 2,500 patients who had potentially been exposed to bloodborne viruses including HIV, hepatitis B, and hepatitis C due to what the agency described as a failure to properly clean ...

For the time being, some patients can only get refills of their ARVS for one week at a time, said Nelson Otwoma, director of the National Empowerment Network of People Living with HIV/AIDS in Kenya.